Abstract. microRNAs (miRNAs) have been suggested to play a vital role in regulating tumor progression and invasion. However, the expression of miR-27a in esophageal squamous cell carcinoma (ESCC) and its effect on the tumorigenesis of ESCC are unclear. In the present study, we found that miR-27a was downregulated in esophageal carcinoma cell lines and ESCC specimens with lymph node metastasis. Furthermore, we demonstrated that miR-27a binds to the 3'-untranslated region (UTR) of KRAS and inhibits the expression of the KRAS protein. miR-27a levels were inversely correlated with levels of KRAS mRNA and protein in ESCC specimens. Both in vitro and in vivo assays revealed that miR-27a attenuated ESCC proliferation, invasion and tumor growth in nude mice. miR-27a exerts its tumor suppressor function through inhibition of the KRAS-related ERK pathways. Our findings suggest, for the first time, that miR-27a suppresses tumorigenesis of ESCC by targeting KRAS. Introduction microRNAs (miRNAs) are an endogenous conserved class of non-coding 20-22 nt small RNAs that regulate gene expression at the post-transcriptional level by mostly binding to 3'-UTR of target mRNAs, leading to mRNA degradation or translation inhibition. Recent reports demonstrate a role for miRNA expression in disease progression and outcome. To date, several miRNA expression profiles in esophageal squamous cell carcinoma (ESCC) have been reported (1,2), and several specific miRNAs have been proven to be involved in ESCC tumorigenesis, including miR-21 (3) and miR-129-2 (4).
Introduction microRNAs (miRNAs) are an endogenous conserved class of non-coding 20-22 nt small RNAs that regulate gene expression at the post-transcriptional level by mostly binding to 3'-UTR of target mRNAs, leading to mRNA degradation or translation inhibition. Recent reports demonstrate a role for miRNA expression in disease progression and outcome. To date, several miRNA expression profiles in esophageal squamous cell carcinoma (ESCC) have been reported (1, 2) , and several specific miRNAs have been proven to be involved in ESCC tumorigenesis, including miR-21 (3) and miR-129-2 (4).
The role of miR-27a in tumorigenesis differs in various cells and tissues. It is regarded as an oncogene in several types of tumors. Liu et al (5) reported that suppression of miR-27a inhibits gastric cancer cell growth by targeting prohibitin; Zhang et al (6) confirmed that the overexpression of miR-27 promotes the metastasis of the human gastric cancer cell line AGS, whereas its depletion decreases cell metastasis. However, miR-27a was found to be downregulated in several other tumor types (reviewed in ref. 7) , including acute promyelocytic leukemia (8) , colorectal cancer (9,10), malignant melanoma (11) , oral squamous cell carcinoma (12) and prostate cancer (13) , indicating it may be a possible tumor suppressor. Most recently, miR-27a was found to target epidermal growth factor receptor (EGFR) (14, 15) , which is activated and promotes tumorigenesis in numerous types of tumors.
To date, there are no report on the role of miR-27a in the tumorigenesis of ESCC. Although Zhang et al (16) showed that the downregulation of miR-27a reversed the multidrug resistance of ESCCs, they did not investigate the expression level of miR-27a in ESCC and its possible role in tumorigenesis.
In the present study, we evaluated the expression of miR-27a in ESCC specimens and cell lines and studied the role of miR-27a in cell growth and migration of esophageal carcinoma cell line TE-1. We also investigated the mechanisms of miR-27a modulation during TE-1 cell growth.
Materials and methods
Cell lines. Primary cultures of normal esophageal epithelial cells (NEECs) were established in our laboratory. NEECs were established from fresh biopsies of adjacent noncancerous esophageal tissue, according to a previous report (17) . The NEECs and ESCCs were grown at 37˚C in 5% CO 2 with keratinocyte serum-free medium, with 40 µg/ml bovine pituitary extract, 1.0 ng/ml epidermal growth factor, 100 U/ml penicillin and 100 µg/ml streptomycin.
The esophageal cancer cell lines, including NECC, TE1, TE13, Eca109, EC9706, KYSE140 and KYSE30, were obtained from the Cell Bank of the Type Culture Collection of the Chinese Academy of Sciences (Shanghai, China). All cell lines were grown in RPMI-1640 medium (Invitrogen, Carlsbad, CA, USA) supplemented with 10% fetal bovine serum, 100 µg/µl streptomycin and 100 µg/µl penicillin in a humidified incubator containing 5% CO 2 at 37˚C. ] relative to U6 snRNA or GAPDH.
Constructs. luc-UTR vectors were constructed by cloning the predicted miR-27a target region or its mutant control into the NheI and SalI sites of the pmirGLO luciferase vector (Promega) using the PCR generated fragments. The oligonucleotide pairs contained the Kpn1 internal site for clone confirmation: sense-wt: 5'-CTAGCTAGGTACCTTGAACT AGCAATGCCTGTGAAAG-3' and antisense-wt: 5'-TCG ACTTTCACAGGCATTGCTAGTTCAAGGTACCTAG-3'; sense-mut: 5'-CTAGCTAGGTACCTTATTATAGCAATG CACACAGAAG-3' and antisense-mut: 5'-TCGACTTCTGT GTGCATTGCTATAATAAGGTACCTAG-3'. Bold indicates NheI and SalI sites; underlining indicates the Kpn1 site; italics indicates the mutated sites.
Synthesized RNA duplexes of scramble miRNA, miR-27a, and their inhibitors anti-scramble and anti-miR-27a were obtained from Baoxin Bio-Technology Co., Ltd. (Zhengzhou, China). To construct a vector expressing miR-27a, the precursor sequence of miR-27a (MI0000085) was synthesized, annealed and then inserted into the BamHI-HindIII fragment of the pGCsi/U6 vector (GeneChem, Shanghai, China). A construct including the non-specific miRNA was used as a negative control. The miR-27a knockdown lentivirus was purchased from Baoxin Bio-Technology.
The KRAS-expressing vector was constructed by cloning full-length KRAS cDNA into the eukaryotic expression vector pcDNA3.1(+) (Invitrogen). The empty pcDNA3.1(+) vector was used as a negative control.
Cell transfection and infection. TE-1 cells were infected with the miR-27a lentivirus or the control lentivirus expressing a scrambled miRNA. All cells were selected with 500 mg/l G418 to generate two stable monoclonal cell lines (a stable cell line expressing miR-27a, TE-1-miR-27a and a control stable cell line, TE-1-scramble).
To establish stable miR-27a knockdown cell lines, TE-1 cells were transduced with the miR-27a knockdown lentivirus or the control lentivirus and selected with 5 mg/l puromycin.
For miRNA and pcDNA3.1-KRAS combination experiments, TE-1-miR-27a and TE-1-scramble cells were transfected with pcDNA3.1-KRAS or empty vector using Lipofectamine 2000 (Invitrogen).
Luciferase assay. TE-1-miR-27a cells were transfected with pmirGLO-KRAS-wt, pmirGLO-KRAS-mut or pmirGLO-ctrl using Lipofectamine 2000 (Invitrogen). Luciferase activity was measured 24 h after transfection using the Dual-Glo luciferase assay system (Promega). The Renilla luciferase activity served as internal control.
MTT assay. Cells were seeded onto 96-well plates at a density of 5x10 4 cells/well in 100 µl medium. All cells were maintained in a humidified 37˚C incubator with 5% CO 2 . 20 µl 3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) solution (5 g/l in phosphate-buffered saline) was added to each well of the microplate, and the absorbance at 570 nm was measured by a microplate reader. After a 4-h incubation, the number of viable cells was measured a point, was set 5 re-wells.
In vitro scratch assay. TE-1 cells (5x10 6 /well) were seeded to 90% confluence in a 6-well plate for overnight culture. The following day a scratch was made through the center of each well using a 200-µl pipette tip, creating an open 'scratch' or 'wound' that was clear of cells. The dislodged cells were removed by three washes with complete culture media, and cells were incubated under standard conditions. Migration into the open area was documented at 72 h postscratching.
Western blot analysis. Western blot analyses were performed as previously described (18) . Antibodies against KRAS (Sigma-Aldrich), ERK (Santa Cruz Biotechnology), phosphorylated ERK (Santa Cruz Biotechnology), and c-Fos (Santa Cruz Biotechnology) were obtained from Cell Signaling Technology. The anti-β-actin antibody was from Santa Cruz Biotechnology.
In vivo tumorigenesis. Five-week-old male nude athymic BALB/c nu/nu mice were used for examining tumorigenicity. To evaluate the role of miR-27a in tumor formation, TE-1-miR-27a cells, TE-1-scramble control, TE-1-anti-miR-27a cells, or TE-1-anti-scramble control were propagated and inoculated subcutaneously into the dorsal flanks of nude mice (2x10 6 cells in a 0.2-ml volume). Tumor size was measured every 5 days. After 30 days, the mice were sacrificed, necropsies were performed and the tumors were weighed. Tumor volumes were determined according to the following formula: A x B 2 /2, where A is the largest diameter and B is the diameter perpendicular to A. The experiments were performed using five mice per group, and all animal procedures were performed in accordance with institutional guidelines.
Statistical analysis. Statistical evaluation of data was performed using SPSS 13 analysis software (SPSS, Chicago, IL, USA). Independent-samples t-test, or paired-samples t-test were used to evaluate statistical significance. Spearman's correlation tests were used to evaluate the pair-wise expression correlation between miR-27a and KRAS. Data are shown as means ± SEM. The significant level was set at P<0.05.
Results

miR-27a is downregulated in ESCC cell lines and clinical specimens.
Published datasets archived in the publicly available Gene Expression Omnibus (GEO) repository were used for re-analysis using GEO2R (NCBI online gene expression tool) (19) . Datasets published in GEO reference series GSE13937 (20) were used for microRNA expression analysis of hsamiR-27a in ESCC compared with adjacent normal esophageal tissues. These datasets used OSU-CCC Human and Mouse MicroRNA Microarray version 3.0 array platform. Normalized signal intensity value was analyzed using the paired-samples t-test analysis. The expression of hsa-miR-27a was decreased in tumors when compared with that in adjacent normal tissues from ESCC patients with nodal involvement (n=20; P=0.041). However, in ESCC patients without nodal involvement, this difference was not significant (n=24; P=0.785) (Fig. 1A) .
We used quantitative real-time PCR (qRT-PCR) to measure mature miR-27a expression levels in ESCC tissues of patients with nodal involvement and cell lines. miR-27a was significantly downregulated in ESCC tissues when compared with the paired adjacent normal tissues (paired-samples t-test, n=25; P=0.025) (Fig. 1B) . In six esophageal carcinoma cell lines, the expression of miR-27a was decreased, particularly in TE-1 cells (independent-samples t-test; P=0.003) (Fig. 1C) .
miR-27a directly targets and inhibits KRAS.
To determine the role of miR-27a in ESCCs, we performed a bioinformatic search (TargetScan and PicTar) to identify putative mRNA 3'-UTR targets for the mature miR-27a. We found that miR-27a had a seed region that matched the 3'-UTR of human KRAS (nucleotides 343-349; NM_033360) ( Fig. 2A) . To verify that KRAS is a direct target of miR-27a, the KRAS 3'-UTR containing the miR-27a binding site was cloned into the pmirGLO control vector downstream of the luciferase ORF. This reporter construct was used to transfect 293 cells. Co-transfection of miR-27a with the wt KRAS 3'-UTR construct in 293 cells resulted in a significant inhibition of luciferase activity compared with the negative control (Fig. 2B) . Mutagenesis of the miR-27a binding site within the KRAS 3'-UTR abolished the ability of miR-27a to regulate the luciferase expression (Fig. 3B) . In addition, overexpression of miR-27a in TE-1 cells strongly reduced the endogenous protein and mRNA levels of KRAS when compared with these levels in the control (Fig. 2C  and D) . In clinical ESCC specimens, there was an inverse correlation between the mRNA/protein levels of KRAS and the level of miR-27a expression (Fig. 2E) . These data suggest that miR-27a acts as a tumor suppressor by targeting KRAS in ESCC.
miR-27a inhibits the ERK pathway. KRAS activation can trigger several important signaling pathways, such as the Ras/Raf/MEK/ERK pathways, most of which regulate cell proliferation, survival and invasion. Therefore, we investi- ]. In the histogram, the miR-27a expression value of normal tissue was set to 1, and the relative expression levels of miR-27a were determined by using the 2 ]. The expression levels of KRAS protein were determined by relative gray level (KRAS/β-actin). All data are shown as means ± SEM. levels of ERK (Fig. 3A) . Results of the western blot analysis demonstrated that miR-27a is a negative regulator of the ERK pathway.
Subsequently, rescue experiments were performed by overexpressing the KRAS vector (without an endogenous 3'-UTR) in miR-27a-treated cells. TE-1 cells were first transfected with miR-27a and then with the KRAS-encoding vector 48 h later. The miR-27a-induced downregulation of KRAS was rescued upon the introduction of KRAS, and the phosphorylation level of ERK was altered in a similar manner (Fig. 3B) . These observations suggest that miR-27a inhibits the ERK pathway by targeting KRAS.
miR-27a suppresses TE-1 cell proliferation and invasion by targeting KRAS.
Overexpression of miR-27a markedly attenuated cell proliferation, and knockdown of miR-27a promoted cell proliferation in TE-1 cells (Fig. 4A) . Forced expression of KRAS (without an endogenous 3'-UTR) rescued the cell growth inhibition of miR-27a partially, suggesting that miR-27a regulates cell growth through targeting KRAS (Fig. 4A) . Scratch assays were used to measure cell migration or to observe the healing of scratches in cancer cell monolayers. Overexpression of miR-27a significantly inhibited the ability of TE-1 cells to heal scratch assays. However, knockdown of miR-27a significantly promoted this behavior (Fig. 4B) . In nude mouse xenograft models, TE-1 cells with miR-27a overexpression developed smaller tumors (both in tumor volume and weight) compared with TE-1 cells with normal miR-27a (scramble). Accordingly, miR-27a knockdown in TE-1 cells promoted tumor formation (both in tumor volume and weight) in the nude mouse xenograft experiments (Fig. 4C) .
Discussion
We first analyzed the miR-27a expression data archived in GEO. GSE13937 recorded the miRNA array data to compare miRNA expression between ESCC and paired adjacent normal tissues. We found that miR-27a was significantly downregulated in ESCCs with nodal involvement. However, miR-27a was not downregulated in ESCCs without nodal involvement. The downregulation of miR-27a is present only in ESCC specimens with nodal involvement, indicating it may participate in the migratory capacity of ESCC. In order to confirm the expression change of miR-27a, we further studied the miR-27a expression in 25 ESCC specimens with nodal involvement using qRT-PCR, and demonstrated miR-27a is downregulated in ESCCs. In six esophageal carcinoma cell lines, the expression of miR-27a was also decreased, particularly in TE-1 cells.
We next explored the possible targets of miR-27a in ESCCs through different computational algorithms. In the present study, we proved that miR-27a targets KRAS directly. KRAS is a GTPase and an early player in many signal transduction pathways. Active GTP-bound KRAS associates with a wide variety of effectors, including Raf, PI3K, Ral-GDS, Rho GTPases and other molecules, to transmit downstream signals that control distinct cellular events, including cell proliferation, survival, differentiation and invasion (21, 22) . KRAS promotes tumorigenesis and has been proven to be downregulated by the let-7 family (23) and miR-96 (24) . ESCC patients (16%) (5/30 cases) were found to harbor KRAS gene mutations (25) . In the present study, we demonstrated that miR-27a may be a negative regulator of the ERK pathway, through targeting KRAS and decreased expression of phosphorylated ERK and its downstream effector c-Fos.
In order to investigate the role of miR-27a in ESCCs, gain and loss of function experiments were conducted. Forced expression of miR-27a significantly decreased the cell proliferation and migration of TE-1 cells, while miR-27a inhibition exerted an opposite effect. In the nude mouse assay, the result was consistent with that in vitro. We hypothesized that miR-27a is a tumor suppressor in ESCCs, although it is regarded as an oncogene in several other tumor types (5, 6) . Our results support the opinion that the same miRNA can have antagonizing roles in two different cell types; i.e. in one cell type the miRNA promotes proliferation whereas in another cell type the same miRNA inhibits proliferation (7).
In conclusion, this is the first study to show that miR-27a inhibits cell proliferation and invasion in ESCC cells. It is also the first study to show that tumor promotor KRAS is negatively regulated by miR-27a at the post-transcriptional level via binding to 3'-UTR of KRAS mRNA in esophageal squamous cell carcinoma cells.
